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METHODS:
We designed a multicentre prospective study in patients selected at the time of catheter insertion. Doppler-US was scheduled at 1 and 6months after insertion and before insertion in case of a previous central line. Blood samplings were drawn at insertion and at 1 and 6months later. RESULTS: One-hundred patients received a TIVAD and 90 completed the 6-month study.
Prevalence of thrombophilia abnormalities and hypercoagulability was found in 50% of the cohorts. Conversely, catheter venous thrombosis frequency was low (6.6%).
CONCLUSION: Our data do not support biological screening at the time of a TIVAD insertion.
We emphasise the contribution of a medical history of venous thromboembolism and prospective Doppler-US for identifying asymptomatic catheter venous thrombosis to select patients who may benefit from biological screening and possible anticoagulant therapy.
Other intravenous and vascular access resources that may be of interest (External links -IVTEAM has no responsibility for content).
Guide for intravenous chemotherapy and associated vascular access devices from Macmillan.
CancerUK IV chemotherapy information.
